Press Releases

ADC Therapeutics Announces Closing of $105 Million Private Financing

ADC Therapeutics Announces Closing of $105 Million Private Financing
Lausanne, Switzerland, October 18, 2016 – ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced that it has raised $105 million through a private placement. The financing was oversubscribed and supported by both new and existing investors, including

ADC Therapeutics Doses First Patient in a Phase I Clinical Trial of ADCT-402 for Patients with B-cell lineage Acute Lymphoblastic Leukemia

ADC Therapeutics Doses First Patient in a Phase I Clinical Trial of ADCT-402 for Patients with B-cell lineage Acute Lymphoblastic Leukemia
- Trial to provide data on safety, tolerability, dosing and efficacy - ADCT-402 also being investigated in a Phase I clinical trial in B-cell lineage non-Hodgkin lymphoma Lausanne, Switzerland, April 12, 2016 – ADC Therapeutics (ADCT), the Swiss-based oncology drug development company, announces that the first patient has been dosed in a Phase I clinical

ADC Therapeutics Doses First Patient in Phase I Trial of ADCT-402 in CD-19 Positive B-cell Non-Hodgkin Lymphomas

ADC Therapeutics Doses First Patient in Phase I Trial of ADCT-402 in CD-19 Positive B-cell Non-Hodgkin Lymphomas
Lausanne, Switzerland, London, UK and Murray Hill, New Jersey, US - March 11, 2016 – ADC Therapeutics (ADCT), the oncology drug development company, announces that the first patient has been dosed in a Phase I trial to evaluate its antibody drug conjugate (ADC) ADCT-402 in B-cell non-Hodgkin Lymphoma (B-NHL). The two stage, open-label trial will

ADC Therapeutics Doses First Patient in Phase I Trial of ADCT-301 in Acute Myeloid Leukemia

ADC Therapeutics Doses First Patient in Phase I Trial of ADCT-301 in Acute Myeloid Leukemia
Lausanne, Switzerland, London, UK and Murray Hill, New Jersey, US - 9 February 2016 – ADC Therapeutics SA (ADCT), the oncology drug development company, announces that the first patient has been dosed in a Phase I trial to evaluate its lead antibody drug conjugate (ADC) ADCT-301 in Acute Myeloid Leukemia (AML). The two stage, Phase